GlaxoSmithKline plc announces changes to its Board and Committees
26 September 2012 | By GlaxoSmithKline
GSK announces the following changes to its Board and Committee structure...
List view / Grid view
News
GSK and Theravance announce FDA acceptance of FF/VI NDA submission in the US for COPD
26 September 2012 | By GlaxoSmithKline
Japanese New Drug Application (JNDA) submitted for COPD and asthma....
Cisbio Bioassays launches epigenetics toolbox
25 September 2012 | By Cisbio Bioassays
Cisbio Bioassays announces the launch of its epigenetics toolbox for use in drug discovery research...
New data from Boehringer Ingelheim and Lilly showcase strength of Diabetes Alliance
25 September 2012 | By Boehringer Ingelheim / Eli Lilly & Company
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present data for three molecules, including two investigational compounds, from their Diabetes Alliance portfolio at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting in Berlin, 1–5 October 2012. Now in its second year, the Boehringer-Lilly Alliance…
Inside Raman seminars at the STFC, Rutherford Appleton Laboratory, 11th and 12th September
24 September 2012 | By Renishaw plc
Celebrating 20 years of Renishaw Raman...
Novo Nordisk opens new research and development centre in China
24 September 2012 | By Novo Nordisk
Novo Nordisk invests an additional 100 million US dollars to expand its state-of-the-art science facilities in Beijing....
Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer
24 September 2012 | By
Data on 13 of its investigational and approved products will be presented at ESMO 2012...
CHMP recommends indication for the use of Trajenta® (linagliptin) tablets
24 September 2012 | By Boehringer Ingelheim / Eli Lilly and Company
Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a Positive Opinion from the European Medicines Agency’s (EMA) medicinal committee recommending expanding the therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin). If approved by the European Commission, this will expand the indicated use of Trajenta® by…
Roche’s Avastin receives positive opinion from CHMP
24 September 2012 | By Roche
For the treatment of women with recurrent, platinum-sensitive ovarian cancer...
ELIQUIS® (apixaban) receives positive opinion from CHMP
24 September 2012 | By Pfizer
For the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation...
Novo Nordisk ranks 4th among the world’s top 20 science employers
24 September 2012 | By Novo Nordisk
Novo Nordisk has been ranked number four on the Science 2012 Top Employer list – up from ninth place last year...
Elan appoints Hans Peter Hasler as Chief Operating Officer
24 September 2012 | By Elan Corporation
Mr. Hasler is currently a non-executive director of the Company and he will retire from the board of directors of the Company...
Registration opens for Pittcon 2013
21 September 2012 | By Pittcon
The Registration Committee is pleased to announce that conferee registration is now open for Pittcon 2013, which will be held March 17-21, 2013...
Daiichi Sankyo announces PRASFIT-ACS results regarding prasugrel in acute coronary syndrome patients undergoing PCI
21 September 2012 | By Daiichi Sankyo
Data from the PRASFIT-ACS study...
Sanofi and TB Alliance announce collaboration to accelerate new treatments against tuberculosis
20 September 2012 | By Sanofi
Sanofi and TB Alliance have announced a new research collaboration agreement...
